Megan E. Daly
Expertise in
12
conditions

Dr. Megan E. Daly

Radiation Oncology
3850 G St, 
Merced, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
12
conditions
3850 G St, 
Merced, CA 

Overview

Dr. Megan E. Daly is a board-certified UCI Health radiation oncologist.She earned her medical degree and completed a residency in radiation oncology at Stanford University School of Medicine.

Dr. Daly is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Gastrostomy, and Microvascular Decompression.

Dr. Daly is board certified in American Board Of Radiology - Radiation Oncology and Radiology Radiation Oncology. She is actively involved in clinical research, co-authoring 122 peer reviewed articles and participating in 11 clinical trials. Dr. Daly is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in CA

Board Certifications

American Board Of Radiology - Radiation Oncology
Radiology Radiation Oncology

Hospital Affiliations

Uci Health-Orange
University Of California Davis Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Megan E. Daly, MD Private Practice
3850 G St, Merced, CA 95340
Other Locations
UCI Health - Fountain Valley
11190 Warner Avenue, Suite 115, Fountain Valley, CA 92708
UCI Health Chao Family Comprehensive Cancer Center
101 The City Drive South, Building 23, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Radiation
Study Phase: Phase 1
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade
UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: IL-2, Pembrolizumab
Study Phase: Phase 1/Phase 2
Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.
Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Radiation, Drug
Study Phase: Phase 1
Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
Enrollment Status: Completed
Publish Date: October 28, 2020
View 9 Less Clinical Trials

122 Total Publications

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
Journal: Oncoimmunology
Published: September 02, 2026
Similar Doctors
Expertise in
37
conditions
Dr. Ruben C. Fragoso
Radiology | Radiation Oncology
Expertise in
37
conditions
Dr. Ruben C. Fragoso
Radiology | Radiation Oncology
Referral may be required
Before you request

Mercy Cancer Center

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-564-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Fragoso is a Radiologist and a Radiation Oncologist practicing medicine in Merced, California. Dr. Fragoso is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Meningioma, Astrocytoma, Radiation Induced Meningioma, and Glioblastoma. Dr. Fragoso is board certified in Radiology Radiation Oncology. Dr. Fragoso is currently accepting new patients.

Expertise in
10
conditions
Dr. Xiao Zhao
Radiation Oncology
Expertise in
10
conditions
Dr. Xiao Zhao
Radiation Oncology
Referral may be required

Raymond C. Tan MD A Professional Corporation

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-384-6528
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Xiao Zhao is a Radiation Oncologist practicing medicine in Merced, California. Dr. Zhao is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, and Endometrial Cancer.

Expertise in
18
conditions
Dr. Arta M. Monjazeb
Radiology | Radiation Oncology
Expertise in
18
conditions
Dr. Arta M. Monjazeb
Radiology | Radiation Oncology
Referral may be required
Before you request

Arta M. Monjazeb, MD Private Practice

Mercy Cancer Center, 3850 G St, 
Merced, CA 
 (2.5 miles away)
209-564-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arta Monjazeb is a Radiologist and a Radiation Oncologist practicing medicine in Merced, California. Dr. Monjazeb is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Bone Tumor, Anal Cancer, and Angiosarcoma. Dr. Monjazeb is board certified in Radiology Radiation Oncology. Dr. Monjazeb is currently accepting new patients.

Frequently Asked Questions about Dr. Megan E. Daly

How do I make an appointment with Dr. Megan E. Daly?

You can book an appointment with Dr. Megan E. Daly by calling their office at 209-564-3601. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Megan E. Daly a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Megan E. Daly is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Megan E. Daly specialize in?

While Dr. Megan E. Daly is a Radiation Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Megan E. Daly participate in research or clinical trials?

Yes. Dr. Megan E. Daly has published 122 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Megan E. Daly's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Megan E. Daly accept my insurance?

Dr. Megan E. Daly accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 209-564-3601 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daly's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile